Automate cytology from sample to result

BD offers a scalable portfolio that automates cytology in your laboratory from sample to result.

The BD SurePath™ Liquid-based Pap Test can be processed according to the throughput and the automation levels needed, ensuring efficiency, precision, and full traceability across instruments from sample to results.

Low- to mid-volume laboratories: Achieve efficiency and precision of cytology testing in your lab

BD PrepMate™: Compact design delivers precise sample transfer.^1,2

Automates the initial step of the unique BD cell enrichment process by mixing, aspirating and dispensing the specimen from BD SurePath™ Collection Vials.
Eliminates manual cap removal, reducing the risk of contamination.
Handles up to 12 samples per cycle.
Intuitive user interface and small footprint.

BD Totalys™ SlidePrep: Efficiency and confidence in slide processing.³

Automates slide preparation and staining and processes BD SurePath™ and non-gynaecological samples.
Accurate reagent pipetting and precise timing for each sample.
Minimal hands-on time allows staff to perform other tasks.
Prepare up to 4 identical slides from the same cell pellet, for additional analyses beyond Pap cytology.

High-volume laboratories: Fulfil your automation needs with full chain of custody across instruments from sample to results

BD Totalys ™ MultiProcessor: Flexibility to meet current and future screening algorithms.^4,5

Automates the unique BD cell enrichment process for BD SurePath™ Liquid-based Pap Test to remove blood, mucus, and inflammatory cells.
Adaptable loading and unloading of samples maximises flexibility.
Process up to 336 samples, with aliquoting for ancillary testing within an 8-hour shift.
Full chain of custody from collection vial to sample outputs.
BD Totalys™ MultiProcessor and BD Totalys™ SlidePrep are aligned in throughput needs.

BD Totalys™ SlidePrep: Efficiency and confidence in slide processing.^4,6

Processes BD SurePath™ and non-gynaecological samples.
Integrates slide creation and staining from an enriched cell pellet.
Allows for random sample loading.
Fully integrates with the BD Totalys™ MultiProcessor to maintain continuous chain of custody.
Completes a single run of 48 slides in approximately 1 hour.
336 stained slides in an 8-hour shift.
BD Totalys™ MultiProcessor and BD Totalys™ SlidePrep are aligned in throughput needs.

BD FocalPoint™ GS Imaging System: Greater efficiency through enhanced slide imaging.^7,8

Automates both conventional and BD SurePath™ Liquid-based Pap Test slide screening.
Ability to triage up to 25% of slides without the requirement for secondary screening.
Provides up to a 31% increase in slides screened per day compared to manual review.
Decrease the ASC-US/LSIL ratio by 42%, leading to more accurate diagnosis.
Increases HSIL+ and cancer detection respectively by 19.6% and 24.5%, reducing false-negative results.

What can BD solutions for cytology testing automation do for your laboratory?

Automation of cytology testing associated with liquid-based cytology (LBC) may help you improve performance and flexibility in your lab thanks to increased consistency, reliability, throughput and walkaway time.^4,9

BD solutions for
HPV testing
LEARN MORE

BD offers integrated end-to-end solutions for every laboratory size and any cervical cancer screening method

ASC-US, atypical squamous cells of undetermined significance; HSIL, high-grade squamous intraepithelial lesions; LBC, liquid-based cytology; LSIL, low-grade squamous intraepithelial lesions; Pap, Papanicolaou.

1. Rabaan AA et al. J Med Microbiol. 2018;67(5):676–80.
2. BD PrepMate™ Automated Accessory Operator’s Manual (500005571).
3. BD Totalys™ SlidePrep Instrument User’s Manual (500005570).
4. BD Totalys™ MultiProcessor User's Manual (8089991).
5. BD Totalys™ MultiProcessor Throughput Testing Characterization Report (TC-14-1054).
6. PrepStain Plus Software – Surepath Regression Test Report (PD-08129-67R).
7. BD FocalPoint™ GS Imaging System Product Insert (500040544).
8. BD FocalPoint™ Slide Profiler Product Insert (7790419402).
9. Hoda RS et al. Diagn Cytopathol. 2013;41(3):257–78.
10. Nance KV. Diagn Cytopathol. 2007;35(3):148–53.
11. Rask J et al. Int J Cancer. 2014;134(9):2168–79.
12. Fremont-Smith M et al. Cancer. 2004;102(5):269–79.
13. Kenyon S et al. Cancer Cytopathol. 2010;118(5):244–9.
14. Moriarty AT et al. Arch Pathol Lab Med. 2009;133(12):1912–6.
15. Rozemeijer K et al. BMJ. 2017;356:j504.
16. Gibb RK and Martens MG. Rev Obstet Gynecol. 2011;4(Suppl 1):S2–S11.
17. Rozemeijer K et al. Cancer Causes Control. 2016;27(1):15–25.